1,720,981 research outputs found
Percutaneous Revascularization of Chronic Total Occlusion of the Left Main Coronary Artery
No full textIntracoronary bivalirudin: a new way to appease the hostile thrombus?
No full textIntracoronary thrombi are a common finding in the setting of acute coronary syndromes and correlate with intraprocedural complications, adverse prognosis and unpredictable response to standard pharmacological and interventional treatment. Interventional cardiologists have learned to fear the so-called hostile thrombus, with its aggressive and unstable behavior often leading to abrupt and refractory vessel closure. Here we report a case series of intracoronary bivalirudin administration to treat massive intracoronary thrombi, leading to rapid clot disappearance and coronary blood flow restoration. Interventional cardiologists might consider intracoronary bivalirudin administration as a bailout strategy during unusual critical situations. (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Stable Ventricular Fibrillation in a Heterotopic Heart Transplant Recipient
No full textWe present an unusual case of ventricular fibrillation in a conscious patient symptomatic for chest pain and shortness of breath. Almost 20 years ago he underwent heterotopic cardiac transplantation for the treatment of severe idiopathic cardiomyopathy. In the precyclosporine era, this technique was extremely useful because of the high rate of graft rejection in which the maintenance of the native heart could prevent patient death. To date, with the improvements in immunosuppressive therapy, it is generally reserved to a specific subset of conditions. A coronary angiography and a cardiac MRI confirmed the diagnosis. Six months follow-up ECG was unchanged suggesting the persistence of a double heart rhythm in the same body
Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system
No full textBioresorbable vascular scaffold; Enhanced stent visualization systems; Overlap; PC
Safety and efficacy of intracoronary bivalirudin administration during primary angioplasty in comparison with a standard treatment with heparin and provisional GP2b3a inhibitors
No full text
Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients.
No full textabstrac
Clinical and biomechanical behavior of a platinum-cromium stent platform in a large all-comers single centre PCI population: insights from the Novara-PROMETEUS registry
No full textAortic rupture after thoracic endovascular repair in a patient with Familial Thoracic Aortic Aneurysm and Dissections type 6 (FTAAD6)
No full textAortic dissection is an uncommon cause of stroke in young
patients, and can lead to a severe prognosis, especially if
not promptly diagnosed and adequately treated. Among the
etiologies that can underlie an arterial dissection in the
young, there are heritable connective tissue disorders
(HCTDs) with increased vascular fragility [1]. Among
them, the Loeys–Dietz syndrome (LDS) is a recently
defined aortic aneurysm syndrome, inherited as an autosomal-
dominant disease, and caused by heterozygous
mutations in various proteins of the transforming growth
factor beta (TGF-b) pathway [2]. We report a case of a
young woman with LDS, which had been unrecognized
until the patient presented to the emergency department
(ED) with focal neurological symptoms due to an acute
ischemic stroke secondary to aortic dissection. The diagnosis
of LDS type 2, confirmed at the molecular level,
offered the opportunity to describe and discuss several causes of arterial dissection in the young, and focus on the
underlying diseases, particularly focusing on this recently
described HCTD
Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: An update
No full textObjectives To perform an updated meta-analysis comparing biodegradable polymer drug eluting stents (BP-DES) and durable polymer drug eluting stents (DP-DES). Background BP-DES have been suggested to reduce late stent thrombosis (LST) rates as compared to first generation DP-DES. Recently, second generation DP-DES have replaced older DES, but comparison of these stents with BP-DES has not yielded consistent results. Methods Medline/Web databases were searched for studies comparing BP-DES and DP-DES, and reporting rates of overall/cardiac mortality, myocardial infarction (MI), LST, target lesion revascularization (TLR) and target vessel revascularization (TVR) and late lumen loss (LLL), with a follow-up >= 6 months. Results Twenty studies (20,005 patients) were included in the meta-analysis. Median follow-up time was 1 year. Compared with DP-DES, BP-DES showed lower LLL (in stent: weighted mean difference WMD -0.45 mm, 95% CI -0.66 to -0.24 mm, P = 0.00001; in segment: WMD -0.15 mm, 95% CI = -0.24 to -0.06 mm, P = 0.001) and lower rates of LST (OR 0.51, 95% CI = 0.30 to 0.86, P = 0.01), although they did not improve mortality, MI, TLR, and TVR rates. BP-DES coated with sirolimus or novolimus, in comparison with biolimus or paclitaxel, were associated with reduced LLL (P < 0.0001 for subgroups). Conclusions In comparison with DP-DES, BP-DES significantly reduce LLL and LST rates, without clear benefits on harder endpoints. The efficacy of BP-DES in preserving lumen patency seems larger for sirolimus and novolimus DES. (c) 2014 Wiley Periodicals, Inc
- …
